Neurodegenerative disease

Related records

Broader conditions (5)

• Central nervous system disorder
• Disease
• Disease by body system or component
• Human disease
• Nervous system disorder

Narrower conditions (920)

• AARS1-related leukoencephalopathy
• ABeta amyloidosis, Arctic type
• ABeta amyloidosis, dutch type
• ABeta amyloidosis, Iowa type
• ABeta amyloidosis, Italian type
• ABetaA21G amyloidosis
• ABetaL34V amyloidosis
• Abetalipoproteinemia
• ABri amyloidosis
• Aceruloplasminemia
• ACO2-related optic atrophy with or without extraocular features
• Acquired human prion disease
• Acquired motor neuron disease
• Acute disseminated encephalomyelitis
• Acute disseminated encephalomyelitis with anti-MOG antibodies
• Acute disseminated encephalomyelitis without anti-MOG antibodies
• Acute hemorrhagic leukoencephalitis
• Acute infantile liver failure-cerebellar ataxia-peripheral sensory motor neuropathy syndrome
• Acute nonparalytic poliomyelitis
• Acute transverse myelitis with anti-MOG antibodies

Trials (442)

• [18F]MC225-PET in Neurodegenerative Disease
• [18F]NIDF PET Imaging in Tau-related Diseases
• [18F]THK-5351 Positron Emission Computed Tomography Study of Normal, Mild Cognitive Impairment, Alzheimer's Disease and Other Neurodegenerative Disease
• A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease
• A Biomarker Study of ATH434 in Participants With MSA
• A Biomarker-chip Assay in Preserved Red Blood Cells for the Diagnosis of Alzheimer's Disease
• A Bridging Study on Efficacy and Safety of [18F]Florbetaben PET for Diagnosis of Alzheimer Disease Subjects in Chinese Population
• A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831
• A Drug-Drug Interaction Study to Assess the CYP1A2 and CYP3A4 Interaction Potential of TEV-56286 (anle138b)
• A FIH Study to Assess the Safety and Tolerability of NS Intravenous NS101 Infusion
• A First in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of ONO-2808-01 in Healthy Participants
• A First Time in Human Study of SNP318 as a Treatment for Neurodegenerative Diseases Including Alzheimer's Disease
• A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
• A First-in-Human Study of Single and Multiple Doses of anle138b in Healthy Subjects
• A Longitudinal Study of Amyotrophic Lateral Sclerosis (ALS) Biomarkers
• A Low-Cost Balance Training Platform Using Augmented Reality in Neurorehabilitation: a Usability Study
• A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of ATTRv Amyloidosis With a V122I or T60A Mutation
• A Multicenter Prospective Registry for the Management of Degenerative Spine Disorders
• A New 3D Virtual Reality-based Upper Limb Training to Improve Dexterity in Parkinson's Disease
• A Open-label Food Effect Study With SEN0014196 in Subjects With Huntington Disease

Approved drugs (2)

• Amifampridine phosphate
• Flortaucipir F 18

Drugs in development (22)

• ANX-005 Phase 1
• Buntanetap Phase 1
• Buntanetap tartrate Phase 1
• Ceperognastat Phase 1
• Dalzanemdor Phase 1
• Dextromethorphan Phase 2
• Etazolate Phase 2
• Flurimedrimer (18F) Phase 1
• Fosmetpantotenate Phase 3
• Ismidenon Phase 1
• Latozinemab Phase 3
• Levacetylleucine Phase 1
• Niacinamide Phase 2
• Pegipanermin Phase 1
• Peptide T Phase 2
• Pimavanserin Phase 3
• Posatirelin Phase 3
• Taurursodiol Phase 1
• Tertomotide Phase 1
• Tilavonemab Phase 1

Other linked drugs (7)

• Amifampridine
• Citicoline
• Dopamine
• Emapunil
• Memantine
• NNZ-2591
• Pyrimidine